SEARCH:   Advanced

Blood, 15 June 2006, Vol. 107, No. 12, pp. 4623-4627. Prepublished online as a Blood First Edition Paper on February 7, 2006; DOI 10.1182/blood-2005-12-4898. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-12-4898v1 107/12/4623    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Stewart, D. A. Articles by Russell, J. A. Search for Related Content PubMed PubMed Citation Articles by Stewart, D. A. Articles by Russell, J. A. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma Douglas A. Stewart, Nizar Bahlis, Karen Valentine, Alex Balogh, Lynn Savoie, Donald G. Morris, Allan Jones, Chris Brown, and James A. Russell From the Departments of Medicine and Oncology, Foothills Medical Centre and Tom Baker Cancer Centre, University of Calgary, AB, Canada. A single center, prospective clinical trial was conducted evaluating 2 cycles of induction high-dose chemotherapy for adults younger than 65 years of age with aggressive non-Hodgkin lymphoma (NHL) and 2 to 3 Age-Adjusted International Prognostic Index risk factors. Patients received one cycle of standard dose cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) followed by one cycle of dose-intensive cyclophosphamide 5.25 g/m2, etoposide 1.05 g/m2, cisplatin 105 mg/m2 (DICEP), then underwent autologous blood stem cell collection, followed by one cycle of high-dose carmustine (BCNU) 300 mg/m2, etoposide 800 mg/m2, Ara-C 1600 mg/m2, melphalan 140 mg/m2 (BEAM), and autologous stem cell transplantation (ASCT) and radiotherapy to prior bulk. From June 1998 to August 2004, 55 patients aged 20 to 63 years (median 44 years) were accrued, 51 (92%) of whom had diffuse large B-cell NHL. Poor prognostic factors included stage 4 (n = 46), elevated lactate dehydrogenase (LDH; n = 47), Eastern Cooperative Oncology Group (ECOG) performance status 2 to 4 (n = 43), bulky mass more than 10 cm (n = 34), and marrow involvement (n = 16). Only one patient experienced nonrelapse mortality. With a median follow-up of 49 months, 4-year event-free survival (EFS) and overall survival (OS) rates for all 55 patients are 72% (95% confidence interval [CI] = 60%-84%) and 79% (95% CI = 69%-90%), respectively. In conclusion, CHOP-DICEP-BEAM is feasible and gave encouraging EFS and OS for patients with poor-prognosis aggressive NHL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: U. Vitolo, A. Chiappella, E. Angelucci, G. Rossi, A. M. Liberati, M. G. Cabras, B. Botto, G. Ciccone, G. Gaidano, L. Falchi, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study Haematologica, September 1, 2009; 94(9): 1250 - 1258. [Abstract] [Full Text] [PDF] C. Haioun, N. Mounier, J. F. Emile, D. Ranta, B. Coiffier, H. Tilly, C. Recher, C. Ferme, J. Gabarre, R. Herbrecht, et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma Ann. Onc., June 30, 2009; (2009) mdp237v1. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020